Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials
Authors:
- Kieran F. DochertyKDKieran F. Docherty
- Ruben Buendia LopezRLRuben Buendia Lopez
- Folke FolkvaljonFFFolke Folkvaljon
- Rudolf A. de BoerRBRudolf A. de Boer
- Martin R. CowieMCMartin R. Cowie
- Ann HammarstedtAHAnn Hammarstedt
- Dalane W. KitzmanDKDalane W. Kitzman
- Mikhail N. KosiborodMKMikhail N. Kosiborod
- Anna Maria LangkildeALAnna Maria Langkilde
- Barry ReicherBRBarry Reicher
- Michele SenniMSMichele Senni
- Sanjiv J. ShahSSSanjiv J. Shah
Open Access
- 1 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (10) , e012349
Abstract
BACKGROUND: Wearable accelerometers can quantify the frequency and intensity of physical activity during everyday life and may provide complementary data to established functional outcome measures on the effect of heart failure therapies on functional limitations. METHODS: In a voluntary substudy of the DETERMINE trials (Dapagliflozin Effect on Exercise Capacity Using a 6-Minute Walk Test in Patients With Heart Failure), patients wore a waist-worn triaxial accelerometer for as long as possible (ideally for 24 h/d for 7 days) at 3 points during the trial, between the screening visit and randomization (baseline data), and during weeks 8 and 14 to 16. Accelerometer outcomes included the change from baseline to week 16 in the total number of steps, time spent in light-to-vigorous physical activity, time spent in moderate-to-vigorous physical activity, movement intensity during walking, number of vector magnitude units‚ and total activity counts. RESULTS: Adequate baseline and week 16 accelerometer data were available for 211 of 817 (26%) randomized patients (defined as ≥10 hours of wear time for ≥3 days). Dapagliflozin had a favorable effect on the mean change from baseline at 16 weeks in the number of steps (between-group difference, 778 [95% CI, 240–1315]), time spent in moderate-to-vigorous physical activity (0.16 [95% CI, 0.03–0.29] hours), and in the mean vector magnitude units (25 [95% CI, 0.1–49] counts per minute). There were no between-group differences in the other accelerometer outcomes of interest. CONCLUSIONS: In this exploratory analysis of the DETERMINE trials, dapagliflozin had a beneficial effect on selected accelerometer-based measures of physical activity in patients with heart failure across the entire left ventricular ejection fraction spectrum, yet did not improve 6-minute walk distance, as previously reported. These data suggest that accelerometer-based measurements of everyday activity may provide complementary information to 6-minute walk distance and identify beneficial effects of treatment not detected by 6-minute walk distance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT03877237 and NCT03877224.Keywords
This publication has 39 references indexed in Scilit:
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection FractionCirculation, 2020
- Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection FractionCirculation, 2019
- Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection FractionCirculation: Heart Failure, 2017
- Isosorbide Mononitrate in Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2015
- Step Detection and Activity Recognition Accuracy of Seven Physical Activity MonitorsPLOS ONE, 2015
- Physical Activity Measured With Implanted Devices Predicts Patient Outcome in Chronic Heart FailureCirculation: Heart Failure, 2014
- Estimating Activity‐related Energy Expenditure Under Sedentary Conditions Using a Tri‐axial Seismic AccelerometerObesity, 2009
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009
- Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic reviewEuropean Heart Journal, 2005
- Assessment of oxygen uptake during the 6-minute walking test in patients with heart failure: Preliminary experience with a portable deviceAmerican Heart Journal, 1997